Compare JPMorgan Equity Premium Income ETF (JEPI) vs Novartis AG (NVS) Price & Performance

JPMorgan Equity Premium Income ETFTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

JPMorgan Equity Premium Income ETF vs Novartis AG — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.62, while Novartis AG trades at $149.81 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while JPMorgan Equity Premium Income ETF pays none, and Novartis AG is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

	JEPI	NVS
Sector	Income / Options Overlay	Health
52-Week High	$59.88	$168.62
52-Week Low	$55.29	$113.50
Market Cap	—	$290.25B
Enterprise Value	—	$330.27B
Dividend Yield	—	3.17%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Equity Premium Income ETF

JEPI trades at $56.39, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages while oscillators remain neutral. The ETF's covered call strategy generates high income but has underperformed the S&P 500 due to sector underweighting and upside caps. Recent news highlights tax inefficiencies and competition from alternatives like SPYI and DIVO.

JEPI's 8% yield appeals to income-focused investors, but total return potential is limited in bull markets. Risks include tracking error, tax disadvantages in taxable accounts, and sector concentration. Analyst sentiment is mixed, with some favoring more dynamic covered-call ETFs for better risk-adjusted returns in current market conditions.

Novartis AG

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JEPI

RYLD ETF's covered call strategy limits small-cap gains compared to direct Russell 2000 ETFs.24/7 Wall Street · 3 days agoBearish JPMorgan Equity Premium ETF underperforms S&P 500 and peers due to sector weight and strategy issues.Seeking Alpha · 4 days agoBearish View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 22 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About JPMorgan Equity Premium Income ETF

JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.